Last reviewed · How we verify
NCT04010669
The Role of Somatostatin in the Hemodynamics of the Hepatic Circulation in Patients Undergoing Liver Resection
Phase 3 trial testing Somatostatin in Portal Hypertension in 40 participants. Status unknown.
31 March 2020
Quick facts
| Lead sponsor | Laikο General Hospital, Athens |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 August 2019 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 July 2020 |
Drugs / interventions tested
- Somatostatin (SOMATOSTATIN) — full drug profile →
- Placebo
Conditions studied
- Portal Hypertension — all drugs for Portal Hypertension →
Sponsor
Laikο General Hospital, Athens
Who can join
18 and older, any sex, with Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the present clinical trial is to study the effect of somatostatin in the regulation of velocity and blood flow of the hepatic circulation in patients undergoing liver resection. The patients will be randomized in two groups: the study group will receive somatostatin and the control group will receive the placebo. In both groups, patients will undergo hepatectomy and directly postoperatively they will receive either somatostatin or placebo, depending on their randomization. The primary endpoint will be the increase or decrease of the velocity and the flow of the hepatic circulation estimated by ultrasonography compared to the same parameters when measured preoperatively.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy.
Hessheimer AJ, Vengohechea J, Martínez de la Maza L, Muñoz J, et al · · 2021 · cited 1× · PMID 34439143 · DOI 10.3390/cancers13163989
Verify or expand the search:
- PubMed search for NCT04010669
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Somatostatin
Trials testing the same drug.
- NCT07304466 — Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation · NA · not yet recruiting
- NCT06416969 — Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation · EARLY_PHASE1 · recruiting
- NCT03998709 — Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion · Phase 4 · withdrawn
- NCT03846180 — Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage · completed
- NCT03241706 — Liver Glycogen and Hypoglycemia in Humans · Phase 1 · active not recruiting
Other recruiting trials for Portal Hypertension
Currently open trials in the same condition.
- NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
- NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
- NCT07419724 — Construction of a Portal Hypertension Biobank · recruiting
- NCT07116096 — Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis · NA · recruiting
- NCT07080697 — A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hyper · NA · recruiting
Other Laikο General Hospital, Athens trials
Trials by the same sponsor.
- NCT07268222 — Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS) · Phase 4 · recruiting
- NCT07316075 — Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas · enrolling by invitation
- NCT04618601 — Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04010669 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Laikο General Hospital, Athens
- Last refreshed: 8 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04010669.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing